CaliPharms Return on Equity

CaliPharms (KGET) currently reports a ROE of 72.64%. That is above the Industrials sector average of 20.47%. Use the charts on this page to explore CaliPharms's ROE history and peer comparisons.

CaliPharms's ROE of 72.64% is higher than the Industrials sector average of 20.47%. That is roughly 254.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but CaliPharms's current 72.64% should be judged against Industrials norms (sector average: 20.47%) and against KGET's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 72.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 20.47%. From there, open related valuation or income-statement pages for CaliPharms, and consider following KGET for alerts when major investors trade the stock.

CaliPharms is classified in the Industrials sector. On ROE, it currently shows 72.64% versus a sector average near 20.47%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing KGET with unrelated industries.